Intergroupe Francophone De Cancerologie Thoracique

This phase 3 trial tested whether patients with advanced non-small cell lung cancer (NSCLC) who received initial immunotherapy (nivolumab and ipilimumab) for 6 months could safely stop treatment and be monitored, instead of continuing therapy indefinitely. The study enrolled 265 …

This study tested the immunotherapy drug durvalumab in 50 patients with advanced lung cancer who were too weak for standard chemotherapy. The goal was to see if the drug is safe and helps control the disease. Researchers focused on side effects and how well patients responded.